Matching articles for "Aristada"
In Brief: Three New Injectable Antipsychotic Drugs
The Medical Letter on Drugs and Therapeutics • December 25, 2023; (Issue 1692)
Three extended-release injectable formulations of
second-generation antipsychotic drugs — two of
risperidone (Rykindo, Uzedy) and one of aripiprazole
(Abilify Asimtufii) — have been approved by the...
Three extended-release injectable formulations of
second-generation antipsychotic drugs — two of
risperidone (Rykindo, Uzedy) and one of aripiprazole
(Abilify Asimtufii) — have been approved by the FDA
for treatment of schizophrenia in adults. Rykindo and
Abilify Asimtufii are also approved for maintenance
treatment of bipolar I disorder in adults. Other
extended-release injectable formulations of
risperidone and aripiprazole have been available in
the US for years (see Table 1).
In Brief: Twice-Yearly Paliperidone (Invega Hafyera) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • January 10, 2022; (Issue 1641)
Invega Hafyera (Janssen), a long-acting, extended-release
(ER) formulation of the second-generation
antipsychotic paliperidone palmitate, has been
approved by the FDA for twice-yearly IM treatment
of...
Invega Hafyera (Janssen), a long-acting, extended-release
(ER) formulation of the second-generation
antipsychotic paliperidone palmitate, has been
approved by the FDA for twice-yearly IM treatment
of schizophrenia in adults who have been adequately
treated with another injectable ER formulation of the
drug (Invega Sustenna or Invega Trinza). It is the first
drug to become available in the US for twice-yearly
treatment of schizophrenia.
Aripiprazole with Digital Ingestion Tracking (Abilify MyCite)
The Medical Letter on Drugs and Therapeutics • January 28, 2019; (Issue 1564)
Monitoring adherence of psychiatric patients to
oral medication may be especially difficult. The
FDA has approved Abilify MyCite (Otsuka/Proteus),
an aripiprazole tablet with an embedded sensor
that tracks...
Monitoring adherence of psychiatric patients to
oral medication may be especially difficult. The
FDA has approved Abilify MyCite (Otsuka/Proteus),
an aripiprazole tablet with an embedded sensor
that tracks when patients take the medication. It is
indicated for treatment of adults with schizophrenia,
bipolar disorder, or major depressive disorder. Abilify MyCite is the first drug with a digital ingestion tracking
system to be approved in the US.
Drugs for Psychotic Disorders
The Medical Letter on Drugs and Therapeutics • December 19, 2016; (Issue 1510)
Oral antipsychotic drugs used for treatment of
schizophrenia, schizoaffective disorder, delusional
disorder, and other manifestations of psychosis or
mania are listed in Table 1. Parenteral
antipsychotic...
Oral antipsychotic drugs used for treatment of
schizophrenia, schizoaffective disorder, delusional
disorder, and other manifestations of psychosis or
mania are listed in Table 1. Parenteral
antipsychotic drugs used for treatment of these
disorders are listed in Table 2.
Two Long-Acting Injectable Antipsychotics for Schizophrenia
The Medical Letter on Drugs and Therapeutics • November 9, 2015; (Issue 1481)
The FDA has approved two new long-acting injectable
formulations of second-generation antipsychotics
for treatment of schizophrenia: aripiprazole lauroxil
(Aristada – Alkermes), which is given once every...
The FDA has approved two new long-acting injectable
formulations of second-generation antipsychotics
for treatment of schizophrenia: aripiprazole lauroxil
(Aristada – Alkermes), which is given once every 4-6
weeks, and paliperidone palmitate (Invega Trinza –
Janssen), which is given once every 3 months.
Once-monthly injectable formulations of aripiprazole
(Abilify Maintena) and paliperidone palmitate (Invega
Sustenna) were approved earlier.